TrialJournal of atherosclerosis and thrombosis2021

Distinct Differences in Lipoprotein Particle Number Evaluation between GP-HPLC and NMR: Analysis in Dyslipidemic Patients Administered a Selective PPARα Modulator, Pemafibrate.

Shizuya Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.